



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Mipasetamab

Cat. No.:	HY-P99733
CAS No.:	2361055-48-1
Target:	TAM Receptor; ADC Antibody
Pathway:	Protein Tyrosine Kinase/RTK; Antibody-drug Conjugate/ADC Related
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Mipasetamab is an IgG1k antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity <sup>[1]</sup> .									
<b>IC<sub>50</sub> &amp; Target</b>	Axl									
<b>In Vitro</b>	<p>ADCT-601 (0.02-9.29 nM; 5 d) shows cytotoxicity on AXL-positive SN12C cells but ont AXL-negative Karpas-299 cells<sup>[1]</sup>. ADCT-601 (0.83 nM; 2-36 h) increases the level of DNA interstrand cross-links time-dependently in SN12C cells<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>AXL-positive SN12C cells: Panc-1, A-172, SK-LU-1, MDA-MB-231, SK-OV-3, NCI-H1299, and SN12C</td> </tr> <tr> <td>Concentration:</td> <td></td> </tr> <tr> <td>Incubation Time:</td> <td>5 days</td> </tr> <tr> <td>Result:</td> <td>Showed in vitro cytotoxicity with IC<sub>50</sub>s of 0.47 nM (Panc-1), 0.59 nM (A-172), 0.02 nM (SK-LU-1), 0.35 nM (MDA-MB-231), 0.11 nM (SK-OV-3), 2.2 nM (NCI-H1299), and 0.83 nM (SN12C), respectively.</td> </tr> </table>		Cell Line:	AXL-positive SN12C cells: Panc-1, A-172, SK-LU-1, MDA-MB-231, SK-OV-3, NCI-H1299, and SN12C	Concentration:		Incubation Time:	5 days	Result:	Showed in vitro cytotoxicity with IC <sub>50</sub> s of 0.47 nM (Panc-1), 0.59 nM (A-172), 0.02 nM (SK-LU-1), 0.35 nM (MDA-MB-231), 0.11 nM (SK-OV-3), 2.2 nM (NCI-H1299), and 0.83 nM (SN12C), respectively.
Cell Line:	AXL-positive SN12C cells: Panc-1, A-172, SK-LU-1, MDA-MB-231, SK-OV-3, NCI-H1299, and SN12C									
Concentration:										
Incubation Time:	5 days									
Result:	Showed in vitro cytotoxicity with IC <sub>50</sub> s of 0.47 nM (Panc-1), 0.59 nM (A-172), 0.02 nM (SK-LU-1), 0.35 nM (MDA-MB-231), 0.11 nM (SK-OV-3), 2.2 nM (NCI-H1299), and 0.83 nM (SN12C), respectively.									
<b>In Vivo</b>	<p>ADCT-601 (3 mg/kg, 6 mg/kg; i.v.; single dose) is safety and tolerability in non-tumor-bearing male Sprague-Dawley rats<sup>[1]</sup>. ADCT-601 (1 mg/kg; i.v.; once daily for 60 days) shows potent and sustained antitumor activity for mouse in both MDA-MB-231 TNBC xenograft model and SN12C renal cancer xenograft model<sup>[1]</sup>. ADCT-601 (0.075, 0.15, or 0.3 mg/kg; i.v.; once daily for 45 days) also dose-dependently in a pancreatic cancer PDX model (PAXF1657) with heterogeneous AXL expression<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Mouse model with SN12C renal cancer xenograft or MDA-MB-231 TNBC xenograft<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>0.3, 0.6, and 1 mg/kg</td> </tr> </table>		Animal Model:	Mouse model with SN12C renal cancer xenograft or MDA-MB-231 TNBC xenograft <sup>[1]</sup>	Dosage:	0.3, 0.6, and 1 mg/kg				
Animal Model:	Mouse model with SN12C renal cancer xenograft or MDA-MB-231 TNBC xenograft <sup>[1]</sup>									
Dosage:	0.3, 0.6, and 1 mg/kg									

---

Administration:	Intravenous injection; once daily for 60 days
Result:	Significantly inhibited the growth of tumor volume in vivo in mouse.

---

## REFERENCES

---

[1]. Zammarchi F, et al. Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers. Mol Cancer Ther. 2022 Apr 1;21(4):582-593.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA